BerGenBio reports Phase II data for bemcentinib plus Keytruda in NSCLC

BerGenBio ASA (OSE:BGBIO) reported data from 15 evaluable patients with advanced non-small cell lung cancer (NSCLC) in the

Read the full 186 word article

User Sign In